Charming Medical Ltd

Charming Medical Limited has announced an Extraordinary General Meeting (EGM) to be held on October 23, 2026. The primary agenda items include the cancellation of 15,000,000 authorized but unissued Class B ordinary shares, a reduction in the total authorized share capital, and the adoption of a new third amended and restated memorandum and articles of association to reflect these changes and remove the dual-class share structure. Shareholders will also vote on a proposal to adjourn the meeting if necessary. The Board of Directors unanimously recommends voting in favor of all proposals.

Charming Medical Ltd. announced significant corporate governance changes, including its election to no longer rely on foreign private issuer exemptions from Nasdaq's corporate governance requirements. The company will now comply with all Nasdaq rules applicable to U.S. domestic issuers. Additionally, the company is abolishing its dual-class share structure, with Ms. Wong surrendering all 2,000,000 Class B ordinary shares, which carried 20 votes each, for no consideration. This will reduce Ms. Wong's aggregate voting power from approximately 91.25% to 68.19%, ensuring one vote per share for all shareholders.

Charming Medical Ltd announced the resignation of Mr. Matthew Mo Kan Tsui as an independent director, effective April 27, 2026, citing other business commitments. The company subsequently appointed Ms. Mei Cai as an independent director, effective May 2, 2026. Ms. Cai, with over 20 years of experience in accounting and finance, will serve as Chairman of the Audit Committee and a member of the Compensation and Nominating Committees.